NCT03375788View on ClinicalTrials.gov

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

July 10, 2024

Study Completion Date

January 10, 2025

Conditions
Non-Alcoholic Fatty Liver DiseaseObesityObesity, AbdominalLiver FatFatty Liver
Interventions
DRUG

Tesamorelin

Tesamorelin F4 formulation 1.4mg daily

DRUG

Identical Placebo

Placebo injection daily

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT03375788 - Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk | Biotech Hunter | Biotech Hunter